Form 4: AEON Biopharma Director Eric G. Carter Receives Stock Options and Restricted Stock Units

Director Eric G. Carter receives stock options and restricted stock units in AEON Biopharma, Inc.

Summary

• On August 31, 2024, Eric G. Carter, a director of AEON Biopharma, Inc., was granted 36,021 shares of Class A Common Stock as restricted stock units.
• These restricted stock units vest in full on the second anniversary of the grant date, contingent upon Carter's continued service.
• Carter also received stock options for 96,210 shares of Class A Common Stock, exercisable at a price of $0.83 per share.
• These options vest in substantially equal monthly installments over the eighteen months following the grant date, also subject to continued service.
• Following these transactions, Carter beneficially owns 36,021 shares of Class A Common Stock and stock options for 96,210 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance and aligning director's interests with shareholders. This is generally viewed positively.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules for both the restricted stock units and stock options incentivize continued service and commitment from the director.

Industry Context

Stock option and restricted stock unit grants are common practices in the biopharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biopharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules, such as the 18-month monthly vesting for the options and the two-year vesting for the restricted stock units, are typical to ensure continued service and commitment.
• Companies like AbbVie, Amgen, and Biogen also use similar equity-based compensation strategies to attract and retain talent.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

AEON Biopharma, Eric G. Carter, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4